Abstract
While a complete understanding of the pathogenesis of Alzheimer’s disease (AD) remains elusive, many conclusions can be drawn from the numerous epidemiological studies undertaken to date. Prevalence and incidence estimates show consistency, following a roughly exponential pattern with a doubling of both parameters roughly every five years after age 65. Roughly 7% of the population aged 65 and over has AD. The clinical course of the disease is reasonably well established and mortality rates rise with increasing levels of cognitive deficit. Four risk factors for AD are firmly established: increasing age, the presence of the apolipoproteinE-4 allele, familial aggregation of cases, and Down’s syndrome. Numerous other associations have been shown in some studies, but not in others. For example, women generally appear at higher risk than men, as do people with lower levels of education; depression is probably prodromal; head injury is an established risk factor, and may interact with the apoE gene; several occupational exposures appear hazardous, and exposure to aluminum in the water supply confers excess risk. Hypertension and other vascular symptoms appear to predispose to AD, which is now seen as nosologically closer to vascular dementia than was previously believed. Several apparently protective factors have been identified, although preventive trials based on these have so far shown minimal effectiveness. The use of non-steroidal anti-inflammatory drugs to treat arthritis is associated with a reduced risk of AD, as is estrogen use by post-menopausal women. Physical activity appears beneficial, as does a diet with high levels of vitamins B6, B12 and folate, while red wine in moderate quantities appears protective. This review concludes with a discussion of the strengths and limitations of current epidemiological methods for studying Alzheimer’s disease.
Similar content being viewed by others
References
Jorm A.F., Korten A.E., Henderson A.S.: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr. Scand. 76: 465–479, 1987.
Gao S., Hendrie H.C., Hall K.S., Hui S.: The relationship between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch. Gen. Psychiatry 55: 809–815, 1998.
Robertson A.: The politics of Alzheimer’s disease: a case study in apocalyptic demography. Int. J. Health Serv. 20: 429–442, 1990.
McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M.: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34: 939–944, 1984.
Erkinjuntti T., Østbye T., Steenhuis R.E., Hachinski V.: The effect of different diagnostic criteria on the prevalence of dementia. N. Engl. J. Med. 337: 1667–1674, 1997.
Hy L.X., Keller D.M.: Prevalence of AD among whites: a summary by levels of severity. Neurology 55: 198–204, 2000.
Andersen K., Nielsen H., Lolk A., Andersen J.T., Becker I., Kragh-Sörensen P.: Incidence of very mild to severe dementia and Alzheimer’s disease in Denmark: the Odense Study. Neurology 52: 85–90, 1999.
Breteler M.M.B.: Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann. N.Y. Acad. Sci. 903: 457–465, 2000.
Di Iorio A., Zito M., Lupinetti M., Abate G.: Are vascular factors involved in Alzheimer’s disease? Facts and theories. Aging Clin. Exp. Res. 11: 345–352, 1999.
Breteler M.M.B., Claus J.J., van Duijn C.M., Launer L.J., Hofman A.: Epidemiology of Alzheimer’s disease. Epidemiol. Rev. 14: 59–82, 1992.
Hofman A., Rocca W.A., Brayne C., Breteler M.M., Clarke M., Cooper B., Copeland J.R., Dartigues J-F., da Silva Droux A., Hagnell O.: The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. EURODEM Prevalence Research Group. Int. J. Epidemiol. 20: 736–748, 1991.
Rocca W.A., Hofman A., Brayne C., Breteler M.M., Clarke M., Copeland J.R., Dartigues J-F., Engedal K., Hagnell O., Heeren T.J.: Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980-1990 prevalence findings. Ann. Neurol. 30: 381–390, 1991.
Lobo A., Launer L.J., Fratiglioni L., Andersen K., Di Carlo A., Breteler M.M., Copeland J.R., Dartigues J-F., Jagger C., Martinez-Lage J.M., Soininen H., Hofman A.: Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 54 (Suppl. 5): S4-S9, 2000.
GAO/HEHS: Alzheimer’s disease: estimates of prevalence in the United States. Washington, United States General Accounting Office. Report GAO/HEHS-98-16, 1998.
Canadian Study of Health and Aging Working Group: Canadian Study of Health and Aging: study methods and prevalence of dementia. Can. Med. Assoc. J. 150: 899–913, 1994.
Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., Taylor J.O.: Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA 262: 2551–2556, 1989.
Larrea F.A., Fisk J.D., Graham J.E., Stadnyk K.: Prevalence of cognitive impairment and dementia as defined by neuropsychological test performance. Neuroepidemiology 19: 121–129, 2000.
Hasegawa K.: The clinical issues of age-related dementia. Tohoku J. Exp. Med. 161 (Suppl.): 29–38, 1990.
Hasegawa K., Homma A., Sato H., Aoba A., Iwai Y., Yamaguchi N., Itami A.: The prevalence study of age-related dementia in the community. Geriatric Psychiatry 1: 94–105, 1984.
Jorm A.F.: Cross-national comparisons of the occurrence of Alzheimer’s and vascular dementias. Eur. Arch. Psychiatry Clin. Neurosci. 240: 218–222, 1991.
Wang W., Wu S., Cheng X., Dai H., Ross K., Du X., Yin W.: Prevalence of Alzheimer’s disease and other dementing disorders in an urban community of Beijing, China. Neuroepi-demiology 19: 194–200, 2000.
Liu H.C., Fuh J.L., Wang S.J., Liu C.Y., Larson E.B., Lin K.N., Wang H.C., Chou P., Wu Z.A., Lin C.H., Wang P.N., Teng E.L.: Prevalence and subtypes of dementia in a rural Chinese population. Alzheimer Dis. Assoc. Disord. 12: 127–134, 1998.
Nakajima K., Ueda Y., Kono I., Tanaka N., Mizuno T., Makino M., Iwamoto H., Mori S., Takanashi Y.: Prevalence of dementia and its subtypes in a rural area in Japan. Jap. J. Geriatrics 35: 530–534, 1998.
Bowen J.D., Malter A.D., Sheppard L., Kukull W.A., McCormick W.C., Teri L., Larson E.B.: Predictors of mortality in patients diagnosed with probable Alzheimer’s disease. Neurology 47: 433–439, 1996.
Østbye T., Hill G., Steenhuis R.E.: Mortality in elderly Canadians with and without dementia: a 5-year follow-up. Neurology 53: 521–526, 1999.
Østbye T., Steenhuis R.E., Wolfson C., Walton R., Hill G.: Predictors of five-year mortality in older Canadians: the Canadian Study of Health and Aging. J. Am. Geriatr. Soc. 47: 1–6, 1999.
Andersen K., Lolk A., Nielsen H., Andersen J., Olsen C., Kragh-Sörensen P.: Prevalence of very mild to severe dementia in Denmark. Acta Neurol. Scand. 96: 82–87, 1997.
Sternberg S.A., Wolfson C., Baumgarten M.: Undetected dementia in community-dwelling older people: the Canadian Study of Health and Aging. J. Am. Geriatr. Soc. 48: 1430–1434, 2000.
Ryan D.H.: Age-specific hospital incidence rates in dementia. A record linkage study of first-admission rates to Scottish hospitals (1968-1987). Dementia 5: 29–35, 1994.
Kokmen E., Chandra V., Schoenberg B.S.: Trends in incidence of dementing illness in Rochester, Minnesota, in three quinquennial periods, 1960-1974. Neurology 38: 975–980, 1988.
Schoenberg B.S., Kokmen E., Okazaki H.: Alzheimer’s disease and other dementing illnesses in a defined United States population: incidence rates and clinical features. Ann. Neurol. 22: 724–729, 1987.
Bickel H., Cooper B.: Incidence and relative risk of dementia in an urban elderly population: findings of a prospective field study. Psychol. Med. 24: 179–192, 1994.
O’Connor D.W., Pollitt P.A., Hyde J.B., Fellows J.L., Miller N.D., Brook C.P.B., Reiss B.B., Roth M.: The prevalence of dementia as measured by the Cambridge Mental Disorders of the Elderly Examination. Acta Psychiatr. Scand. 79: 190–198, 1989.
Nilsson L.V.: Incidence of severe dementia in an urban sample followed from 70 to 79 years of age. Acta Psychiatr. Scand. 70: 478–486, 1984.
Hagnell O., Öjesjö L., Rorsman B.: Incidence of dementia in the Lundby Study. Neuroepidemiology 11 (Suppl. 1): 61–66, 1992.
Aevarsson O., Skoog I.: A population-based study on the incidence of dementia disorders between 85 and 88 years of age. J. Am. Geriatr. Soc. 44: 1455–1460, 1996.
Fratiglioni L., Viitanen M., von Strauss E., Tontodonati V., Herlitz A., Winblad B.: Very old women at highest risk of dementia and Alzheimer’s disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 48: 132–138, 1997.
Mölsä P.K., Marttila R.J., Rinne U.K.: Epidemiology of dementia in a Finnish population. Acta Neurol. Scand. 65: 541–552, 1982.
Fichter M.M., Schröppel H., Meller I.: Incidence of dementia in a Munich community sample of the oldest old. Eur. Arch. Psychiatry Clin. Neurosci. 246: 320–328, 1996.
Morgan K., Lilley J.M., Arie T., Byrne E.J., Jones R., Waite J.: Incidence of dementia in a representative British sample. Br. J. Psychiatry 163: 467–470, 1993.
Copeland J.R.M., Davidson I.A., Dewey M.E., Gilmore C., Larkin B.A., McWilliam C., Saunders P.A., Scott A., Sharma V., Sullivan C.: Alzheimer’s disease, other dementias, depression and pseudo-dementia: prevalence, incidence and three-year outcome in Liverpool. Br. J. Psychiatry 161: 230–239, 1992.
Copeland J.R.M., Dewey M.E., Davidson I.A., Saunders P.A., Scott A.: Geriatric Mental State-AGECAT: prevalence, incidence and long-term outcome of dementia and organic disorders in the Liverpool study of continuing health in the community. Neuroepidemiology 11 (Suppl.1): 84–87, 1992.
Clarke D., Morgan K., Lilley J., Arie T., Jones R., Waite J., Prettyman R.: Dementia and ‘borderline dementia’ in Britain: 8–year incidence and post–screening outcomes. Psychol. Med. 26: 829–835, 1996.
Paykel E.S., Brayne C., Huppert F.A., Gill C., Barkley C., Gehlhaar E., Beardsall L., Girling D.M., Pollitt P., O’Connor D.: Incidence of dementia in a population older than 75 years in the United Kingdom. Arch. Gen. Psychiatry 51: 325–332, 1994.
Brayne C., Gill C., Huppert F.A., Barkley C., Gehlhaar E., Girling D.M., O’Connor D.W., Paykel E.S.: Incidence of clinically diagnosed subtypes of dementia in an elderly population: Cambridge Project for Later Life. Br. J. Psychiatry 167: 255–262, 1995.
Ott A., Breteler M.B., van Harskamp F., Stijnen T., Hofman A.: Incidence and risk of dementia: the Rotterdam Study. Am. J. Epidemiol. 147: 574–580, 1998.
Letenneur L., Jacqmin H., Commenges D., Barberger-Gateau P., Dartigues J-F., Salamon R.: Cerebral and functional aging: first results on prevalence and incidence of the Paquid cohort. Meth. Inform. Med. 32: 249–251, 1993.
Letenneur L., Commenges D., Dartigues J-F., Barberger-Gateau P.: Incidence of dementia and Alzheimer’s disease in elderly community residents of south-western France. Int. J. Epidemiol. 23: 1256–1261, 1994.
Letenneur L., Gilleron V., Commenges D., Helmer C., Orgogozo J.M., Dartigues J-F.: Are sex and educational level independent predictors of dementia and Alzheimer’s disease? Incidence data from the PAQUID project. J. Neurol. Neu-rosurg. Psychiatry 66: 177–183, 1999.
Aronson M.K., Ooi W.L., Geva D.L., Masur D., Blau A., Frishman W.: Dementia: age-dependent incidence, prevalence, and mortality in the old old. Arch. Intern. Med. 151: 989–992, 1991.
Sayetta R.B.: Rates of senile dementia - Alzheimer’s type in the Baltimore longitudinal study. J. Chronic Dis. 39: 271–286, 1986.
Hebert L.E., Scherr P.A., Beckett L.A., Albert M.S., Pilgrim D.M., Chown M.F., Funkenstein H.H., Evans D.A.: Age-specific incidence of Alzheimer’s disease in a community population. JAMA 273: 1354–1359, 1995.
Bachman D.L., Wolf P.A., Linn R.T., Knoefel J.E., Cobb J.L., Belanger A.J., White L.R., D’Agostino R.B.: Incidence of dementia and probable Alzheimer’s disease in a general population: the Framingham Study. Neurology 43: 515–519, 1993.
Kokmen E., Beard C.M., O’Brien P.C., Offord K.P., Kurland L.T.: Is the incidence of dementing illness changing? A 25-year time trend study in Rochester, Minnesota (1960-1984). Neurology 43: 1887–1892, 1993.
Fillenbaum G.G., Heyman A., Huber M.S., Woodbury M.A., Leiss J., Schmader K.E., Bohannon A., Trapp-Moen B.: The prevalence and 3-year incidence of dementia in older black and white community residents. J. Clin. Epidemiol. 51: 587–595, 1998.
Kawas C., Brookmeyer R., Fozard J., Zonderman A.: Age-specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 54: 2072–2077, 2000.
Canadian Study of Health and Aging Working Group: The incidence of dementia in Canada. Neurology 55: 66–73, 2000.
Fukunishi I., Hayabara T., Hosokawa K.: Epidemiological surveys of senile dementia in Japan. Int. J. Soc. Psychiatry 37: 51–56, 1991.
Li G., Shen Y.C., Chen C.H., Zhau Y.W., Li S.R., Lu M.: A three-year follow-up study of age-related dementia in an urban area of Beijing. Acta Psychiatr. Scand. 83: 99–104, 1991.
Shen Y.C., Li G., Li Y.T., Chen C.H., Li S.R., Zhao Y.W., Zhang W.X.: Epidemiology of age-related dementia in China. Chin. Med. J. 107: 60–64, 1994.
Jorm A.F., Jolley D.: The incidence of dementia: a meta-analysis. Neurology 51: 728–733, 1998.
Fratiglioni L., Launer L.J., Anderson K., Breteler M.M.B., Copeland J.R.M., Dartigues J-F., Lobo A., Martinez-Lage J.M., Soininen H., Hofman A.: Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 54 (Suppl. 5): S10-S15, 2000.
Jagger C., Clarke M., Anderson J.: Incidence of dementia in Melton Mowbray: a proposed study and its problems. Neuroepidemiology 11 (Suppl. 1): 57–60, 1992.
Martyn C.N., Pippard E.C.: Usefulness of mortality data in determining the geography and time trends of dementia. J. Epidemiol. Community Health 42: 134–137, 1988.
Raiford K., Anton-Johnson S., Haycox Z., Nolan K., Schaffer A., Caimano C., Fillenbaum G., Heyman A.: CERAD part VII: Accuracy of reporting dementia on death certificates of patients with Alzheimer’s disease. Neurology 44: 2208–2209, 1994.
Macera C.A., Sun R.K.P., Yeager K.K., Brandes D.A.: Sensitivity and specificity of death certificate diagnoses for dementing illnesses, 1988-1990. J. Am. Geriatr. Soc. 40: 479–481, 1992.
Jorm A.F., Korten A.E.: A method for calculating projected increases in the number of dementia sufferers. Aust. N.Z. J. Psychiatry 22: 183–189, 1988.
Brookmeyer R., Gray S.: Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer’s disease. Stat. Med. 19: 1481–1493, 2000.
Brookmeyer R., Gray S., Kawas C.: Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88: 1337–1342, 1998.
van Duijn C.M.: Epidemiology of the dementias: recent developments and new approaches. J. Neurol. Neurosurg. Psychiatry 60: 478–488, 1996.
Hux M.J., O’Brien B.J., Iskedjian M., Goeree R., Gagnon M., Gauthier S.: Relation between severity of Alzheimer’s disease and costs of caring. Can. Med. Assoc. J. 159: 457–465, 1998.
Taylor D.H., Sloan F.A.: How much do persons with Alzheimer’s disease cost Medicare? J. Am. Geriatr. Soc. 48: 639–646, 2000.
Gutterman E.M., Markowitz J.S., Lewis B., Fillit H.: Cost of Alzheimer’s disease and related dementia in managed-medicare. J. Am. Geriatr. Soc. 47: 1065–1071, 1999.
Tomlinson B.E., Blessed G., Roth M.: Observations on the brains of nondemented old people. J. Neurol. Sci. 7: 287–307, 1968.
Rosenberg R.N.: The molecular and genetic basis of AD: the end of the beginning. The 2000 Wartenberg lecture. Neurology 54: 2045–2054, 2000.
Brayne C., Calloway P.: Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer’s type: a continuum. Lancet 1: 1265–1267, 1988.
Ebly E.M., Parhad I.M., Hogan D.B., Fung T.S.: Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology 44: 1593–1600, 1994.
Ritchie K., Kildea D.: Is senile dementia “age-related” or “ageing-related”? Evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 346: 931–934, 1995.
Hall K., Gureje O., Ogunniyi A., Hui S.L., Baiyewu O., Unverzagt F.W., Oluwole S., Hendrie H.C.: Risk factors and Alzheimer’s disease: a comparative study of two communities. Aust. N.Z. J. Psychiatry 32: 698–706, 1998.
Carney J.M.: Oxidative stress leading to loss of critical proteases in Alzheimer’s disease: an alternative view of the etiology of AD. Ann. N.Y. Acad. Sci. 924: 160–163, 2000.
Henderson A.S.: Epidemiology of dementia disorders. Adv. Neurol. 51: 15–25, 1990.
Rocca W.A., van Duijn C.M., Clayton D., Chandra V., Fratiglioni L., Graves A.B., Heyman A., Jorm A.F., Kokmen E., Kondo K., Mortimer J.A., Shalat S.L., Soininen H., Hofman A.: Maternal age and Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20 (Suppl. 2): S21-S27, 1991.
van Duijn C.M., Hofman A.: Risk factors for Alzheimer’s disease: The EURODEM collaborative re-analysis of case-control studies. Neuroepidemiology 11 (Suppl. 1): 106–113, 1992.
Sulkava R., Wikström J., Aromaa A., Raitasalo R., Lehtinen V., Lahtela K., Palo J.: Prevalence of severe dementia in Finland. Neurology 35: 1025–1029, 1985.
Bachman D.L., Wolf P.A., Linn R., Knoefel J.E., Cobb J., Belanger A., D’Agostino R.B., White L.R.: Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 42: 115–119, 1992.
Weissman M.M., Myers J.K., Tischler G.L., Holzer C.E.III., Leaf P.J., Orvaschel H., Brody J.A.: Psychiatric disorders (DSM-III) and cognitive impairment among the elderly in a U.S. urban community. Acta Psychiatr. Scand. 71: 366–379, 1985.
McGonigal G., Thomas B., McQuade C., Starr J.M., MacLennan W.J., Whalley L.J.: Epidemiology of Alzheimer’s presenile dementia in Scotland, 1974-88. BMJ 306: 680–683, 1993.
Roelands M., Baro F., Dom H., Wostyn P.: Epidemiology research on dementia in Antwerp, Belgium. Neuroepidemiology 11 (Suppl. 1): 48–51, 1992.
Gussekloo J., Heeren T.J., Izaks G.J., Ligthart G.J., Rooijmans H.G.: A community based study of the incidence of dementia in subjects aged 85 years and over. J. Neurol. Neu-rosurg. Psychiatry 59: 507–510, 1995.
Bettini R., Gobbi G., Landonio M., Vezzetti V.: Epidemiology of pathological cerebral impairment. Clin. Ther. 140: 225–233, 1992.
Shaji S., Promodu K., Abraham T., Roy K.J., Verghese A.: An epidemiological study of dementia in a rural community in Kerala, India. Br. J. Psychiatry 168: 745–749, 1996.
Park J., Ko H.J., Park Y.N., Jung C.H.: Dementia among the elderly in a rural Korean community. Br. J. Psychiatry 164: 796–801, 1994.
Graves A.B., Larson E.B., Edland S.D., Bowen J.D., Mc-Cormick W.C., McCurry S.M., Rice M.M., Wenzlow A., Uomoto J.M.: Prevalence of dementia and its subtypes in the Japanese American population of King County, Washington state. The Kame Project. Am. J. Epidemiol. 144: 760–771, 1996.
Prencipe M., Casini A.R., Ferretti C., Lattanzio M.T., Fiorel-li M., Culasso F.: Prevalence of dementia in an elderly rural population: effects of age, sex, and education. J. Neurol. Neu-rosurg. Psychiatry 60: 628–633, 1996.
Prineas R.J., Demirovic J., Bean J.A., Duara R., Gomez-Marin O., Loewenstein D., Sevush S., Stitt F., Szapocznik J.: South Florida Program on Aging and Health. Assessing the prevalence of Alzheimer’s disease in three ethnic groups. J. Florida Med. Assoc. 82: 805–810, 1995.
Breitner J.C., Wyse B.W., Anthony J.C., Welsh-Bohmer K.A., Steffens D.C., Norton M.C., Tschanz J.T., Plassman B.L., Meyer M.R., Skoog I., Khachaturian A.: APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 53: 321–331, 1999.
Alpérovitch A., Berr C.: Risk factors of Alzheimer’s disease. Epidemiologic approach [French]. Bulletin de l’Academie Nationale de Medecine 180: 1673–1680, 1996.
van Duijn C.M., Clayton D., Chandra V., Fratiglioni L., Graves A.B., Heyman A., Jorm A.F., Kokmen E., Kondo K., Mortimer J.A., Rocca W.A., Shalat S.L., Soininen H., Hofman A.: Familial aggregation of Alzheimer’s disease and related disorders: a collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20 (Suppl. 2): S13-S20, 1991.
Breitner J.C., Gatz M., Bergem A.L., Christian J.C., Mortimer J., McClearn G.E., Heston L.L., Welsh K.A., Anthony J.C., Folstein M.F.: Use of twin cohorts for research in Alzheimer’s disease. Neurology 43: 261–267, 1993.
Raiha I., Kaprio J., Koskenvuo M., Rajala T., Sourander L.: Alzheimer’s disease in Finnish twins. Lancet 347: 573–578, 1996.
Bergem A.L., Engedal K., Kringlen E.: The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study. Arch. Gen. Psychiatry 54: 264–270, 1997.
Breitner J.C., Murphy E.A.: Twin studies of Alzheimer disease: II. Some predictions under a genetic model. Am. J. Med. Genet. 44: 628–634, 1992.
Breitner J.C., Welsh K.A.: Genes and recent developments in the epidemiology of Alzheimer’s disease and related dementia. Epidemiol. Rev. 17: 39–47, 1995.
Lannfelt L., Pedersen N.L., Lilius L., Axelman K., Johansson K., Viitanen M., Gatz M.: Apolipoprotein epsilon 4 allele in Swedish twins and siblings with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 9: 166–169, 1995.
Roses A.D.: Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu. Rev. Med. 47: 387–400, 1996.
Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C.J., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E.: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7: 180–184, 1994.
Buttini M., Akeefe H., Lin C., Mahley R.W., Pitas R.E., Wyss-Coray T., Mucke L.: Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neu-rodegenerative disease. Neurosci. 97: 207–210, 2000.
Graham D.I., Horsburgh K., Nicoll J.A., Teasdale G.M.: Apolipoprotein E and the response of the brain to injury. Ac-ta Neurochirur. (Suppl.) 73: 89–92, 1999.
Farrer L.A., Cupples A., Haines J.L.: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 278: 1349–1356, 1997.
Weiner M.F., Vega G., Risser R.C., Honig L.S., Cullum C.M., Crumpacker D., Rosenberg R.N.: Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer’s disease. Biol. Psychiatry 45: 633–638, 1999.
Small B.J., Graves A.B., McEvoy C.L., Crawford F.C., Mullan M., Mortimer J.A.: Is APOE-epsilon4 a risk factor for cognitive impairment in normal aging? Neurology 54: 2082–2088, 2000.
Brayne C., Harrington C.R., Wischik C.M., Huppert F.A., Chi L.Y., Xuereb J.H., O’Connor D.W., Paykel E.S.: Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Dementia 7: 169–174, 1996.
Tierney M.C., Szalai J.P., Snow W.G., Fisher R.H., Tsuda T., Chi H., McLachlan D.R., St.George-Hyslop P.H.: A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 46: 149–154, 1996.
Jarvik G.P., Wijsman E.M., Kukull W.A., Schellenberg G.D., Yu C., Larson E.B.: Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case-control study. Neurology 45: 1092–1096, 1995.
Sahota A., Yang M., Gao S., Hui S.L., Baiyewu O., Guerje O., Oluwole S., Ogunniyi A., Hall K.S., Hendrie H.C.: Apolipoprotein E-associated risk for Alzheimer’s Disease in the African-American population is genotype dependent. Ann. Neurol. 42: 659–661, 1997.
Osuntokun B.O., Sahota A., Ogunniyi A.O., Gureje O., Baiyewu O., Adeyinka A., Oluwole S.O., Komolafe O., Hall K.S., Unverzagt F.W., Hui S.L., Yang M., Hendrie H.C.: Lack of an association between Apolipoprotein E 4 and Alzheimer’s Disease in elderly Nigerians. Ann. Neurol. 38: 463–465, 1995.
Maestre G., Ottman R., Stern Y., Gurland B., Chun M., Tang M., Shelanski M., Tycko B., Mayeux R.: Apolipoprotein E and Alzheimer’s disease: ethnic variation in genotypic risks. Ann. Neurol. 37: 254–259, 1995.
Mayeux R., Ottman R., Maestre G., Ngai C., Tang M., Ginsberg H., Chun M., Tycko B., Shelanski M.: Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer’s disease. Neurology 45: 555–557, 1995.
Tang M., Maestre G., Tsai W.Y., Liu X.H., Feng L., Chung W.Y., Chun M., Schofield P., Stern Y., Tycko B., Mayeux R.: Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer’s disease. Ann. N.Y. Acad. Sci. 802: 6–15, 1996.
Yaffe K., Haan M., Byers A., Tangen C., Kuller L.: Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 54: 1949–1953, 2000.
Ott A., Stolk R.P., Hofman A., van H.F., Grobbee D.E., Breteler M.M.: Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39: 1392–1397, 1996.
Stewart R., Prince M., Mann A.: Vascular risk factors and Alzheimer’s disease. Aust. N.Z. J. Psychiatry 33: 809–813, 1999.
Hachinski V., Munoz D.: Vascular factors in cognitive impairment - where are we now? Ann. N.Y. Acad. Sci. 903: 1–5, 2000.
Emery V.O., Gillie E.X., Smith J.A.: Interface between vascular dementia and Alzheimer syndrome: nosologic redefinition. Ann. N.Y. Acad. Sci. 903: 229–238, 2000.
Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., Nissinen A.: Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology 17: 14–20, 1998.
Bonarek M., Baberger-Gateau P., Letenneur L., Deschamps V., Iron A., Dubroca B., Dartigues J-F.: Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepi-demiology 19: 141–148, 2000.
Jorm A.F., van Duijn C.M., Chandra V., Fratiglioni L., Graves A.B., Heyman A., Kokmen E., Kondo K., Mortimer J.A., Rocca W.A., Shalat S.L., Soininen H., Hofman A.: Psychiatric history and related exposures as risk factors for Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20 (Suppl. 2): S43-S47, 1991.
Jorm A.F.: Is depression a risk factor for dementia or cognitive decline? A review. Gerontology 46: 219–227, 2000.
Roberts G.W., Gentleman S.M., Lynch A.: Beta-amyloid protein deposition in the brain after severe head injury. J. Neurol. Neurosurg. Psychiatry 57: 419–425, 1994.
Horsburgh K., Cole G.M., Yang F., Savage M.J., Greenberg B.D., Gentleman S.M., Graham D.I., Nicoll J.A.: beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury. Neuropathol. Appl. Neurobiol. 26: 124–132, 2000.
Graham D.I., Gentleman S.M., Nicoll J.A., Royston M.C., McKenzie J.E., Roberts G.W., Griffin W.S.: Altered be-ta-APP metabolism after head injury and its relationship to the aetiology of Alzheimer’s disease. Acta Neurochirur. Suppl. 66: 96–102, 1996.
Mortimer J.A., van Duijn C.M., Chandra V., Fratiglioni L., Graves A.B., Heyman A., Jorm A.F., Kokmen E., Kondo K., Rocca W.A., Shalat S.L., Soininen H., Hofman A.: Head trauma as a risk factor for Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20 (Suppl. 2): S28-S35, 1991.
Rasmusson D.X., Brandt J., Martin D.B., Folstein M.F.: Head injury as a risk factor in Alzheimer’s disease. Brain Injury 9: 213–219, 1995.
van Duijn C.M., Tanja T.A., Haaxma R., Schulte W., Saan R.J., Lameris A.J., Antonides-Hendriks G., Hofman A.: Head trauma and the risk of Alzheimer’s disease. Am. J. Epidemiol. 135: 775–782, 1992.
O’Meara E.S., Kukull W., Sheppard L., Bowen J.D., McCormick W.C., Teri L., Pfanschmidt M., Thompson J.D., Schellenberg G.D., Larson E.B.: Head injury and risk of Alzheimer’s disease by Apolipoprotein E Genotype. Am. J. Epidemiol. 146: 373–384, 1997.
Chandra V., Kokmen E., Schoenberg B.S.: Head trauma with loss of consciousness as a risk factor for Alzheimer’s disease. Neurology 39: 1576–1578, 1989.
Schofield P.W., Tang M., Marder K., Bell K., Dooneief G., Chun M., Sano M., Stern Y., Mayeux R.: Alzheimer’s disease after remote head injury: an incidence study. J. Neurol. Neurosurg. Psychiatry 62: 119–124, 1997.
Nicoll J.A., Roberts G.W., Graham D.I.: Amyloid beta-protein, APOE genotype and head injury. Ann. N.Y. Acad. Sci. 777: 271–275, 1996.
Guo Z., Cupples L.A., Kurz A., Auerbach S.H., Volicer L., Chui H., Green R.C., Sadovnick A.D., Duara R., DiCarli C., Johnson K., Go R.C., Growdon J.H., Haines J.L., Kukull W.A.: Head injury and the risk of AD in the MIRAGE study. Neurology 54: 1316–1323, 2000.
Brayne C.: Research and Alzheimer’s disease: an epidemiological perspective. Psychol. Med. 23: 287–296, 1993.
Canadian Study of Health and Aging: The Canadian Study of Health and Aging: risk factors for Alzheimer’s disease in Canada. Neurology 44: 2073–2080, 1994.
Sobel E., Davanipour Z., Sulkava R., Erkinjuntti T., Wikström J., Henderson V.W., Buckwalter G., Bowman J.D., Lee P.J.: Occupations with exposure to electromagnetic fields: a possible risk factor for Alzheimer’s disease. Am. J. Epidemiol. 142: 515–524, 1995.
Sobel E., Dunn M., Davanipour Z., Qian Z., Chui H.C.: Elevated risk of Alzheimer’s disease among workers with likely electromagnetic field exposure. Neurology 47: 1477–1481, 1996.
Sobel E., Davanipour Z.: Electromagnetic field exposure may cause increased production of amyloid beta and eventually lead to Alzheimer’s disease. Neurology 47: 1594–1600, 1996.
Dunea G., Mahurkar S.D., Mamdani B., Smith E.C.: Role of aluminum in dialysis dementia. Ann. Intern. Med. 88: 502–504, 1978.
Copestake P.: Aluminium and Alzheimer’s disease - an update. Food Chem. Toxicol. 31: 679–683, 1993.
Edwardson J.A.: The pathogenesis of cerebral beta-amyloid deposition and the possible role of aluminium. In: Lord Walton of Detchant (Ed.), Alzheimer’s disease and the environment. Royal Society of Medicine Sciences, London, 1991, pp. 24-34.
Lord Walton: Chairman’s conclusions. In: Lord Walton of Detchant (Ed.), Alzheimer’s disease and the environment. Royal Society of Medicine Sciences, London, 1991, pp. 163-166.
Doll R.: Review: Alzheimer’s disease and environmental aluminium. Age Ageing 22: 138–153, 1993.
Still C.N., Kelley P.: On the incidence of primary degenerative dementia vs water fluoride content in South Carolina. Neurotoxicology 4: 123–131, 1980.
Martyn C.N., Barker D.J.P., Osmond C., Harris E.C., Edwardson J.A., Lacey R.F.: Geographical relation between Alzheimer’s disease and aluminium in drinking water. Lancet 1: 59–62, 1989.
Vogt T.: Water quality and health: study of a possible relationship between aluminium in drinking water and age-related dementia. Statistik Sentralbyra, Oslo-Kongsvinger, Norway, 1986.
Neri L.C., Hewitt D.: Aluminium, Alzheimer’s disease, and drinking water. Lancet 338: 390, 1991.
Wettstein A., Aeppli J., Gautschi K., Peters M.: Failure to find a relationship between mnestic skills of octogenarians and aluminum in drinking water. Int. Arch. Occup. Environ. Health 63: 97–103, 1991.
Jacqmin H., Commenges D., Letenneur L., Barberger-Gateau P., Dartigues J-F.: Components of drinking water and risk of cognitive impairment in the elderly. Am. J. Epidemiol. 139: 48–57, 1994.
Jacqmin-Gadda H., Commenges D., Letenneur L., Dartigues J-F.: Silica and aluminum in drinking water and cognitive impairment in the elderly. Epidemiology 7: 281–285, 1996.
Rondeau V., Commenges D., Jacqmin-Gadda H., Dartigues J-F.: Relation between aluminum concentrations in drinking water and Alzheimer’s disease: an 8-year follow-up study. Am. J. Epidemiol. 152: 59–66, 2000.
Forbes W.F., Hill G.: The link between aluminum and Alzheimer’s disease. Mature Medicine March/April: 38–41, 1998.
Rifat S.L., Eastwood M.R., Crapper McLachlan D.R., Corey P.N.: Effect of exposure of miners to aluminium powder. Lancet 336: 1162–1165, 1990.
Graves A.B., White E., Koepsell T.D.: The association between aluminum-containing products and Alzheimer’s disease. J. Clin. Epidemiol. 43: 35–44, 1990.
Heyman A., Wilkinson W.E., Stafford J.A., Helms M.J., Sigmon A.H., Weinberg T.: Alzheimer’s disease: a study of epidemiological aspects. Ann. Neurol. 15: 335–341, 1984.
Amaducci L.A., Fratiglioni L., Rocca W.A., Fieschi C., Livrea P., Pedone D., Bracco L.: Risk factors for clinically diagnosed Alzheimer’s disease: a case-control study of an Italian population. Neurology 36: 922–931, 1986.
Broe G.A., Henderson A.S., Creasy H., McCusker E., Korten A.E., Jorm A.F., Longley W., Anthony J.C.: A case-control study of Alzheimer’s disease in Australia. Neurology 40: 1698–1707, 1990.
McLachlan D.R.C., Dalton A.J., Kruck T.P.A.: Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 337: 1304–1308, 1991.
Beard C.M., Kokmen E., Offord K.P., Kurland L.T.: Lack of association between Alzheimer’s disease and education, occupation, marital status, or living arrangement. Neurology 42: 2063–2068, 1992.
Fratiglioni L., Grut M., Forsell Y., Viitanen M., Grafström M., Holmën K., Ericsson K., Bäckman L., Ahlbom A., Winblad B.: Prevalence of Alzheimer’s disease and other dementias in an elderly urban population: relationship with age, sex, and education. Neurology 41: 1886–1892, 1991.
Knoefel J.E., Wolf P.A., Linn R.T.: Education has no effect on incidence of dementia and Alzheimer’s disease in the Framingham study. Neurology 41 (Suppl. 1): 322–333, 1991.
Zhang M., Katzman R., Salmon D., Jin H., Cai G., Wang Z., Qu G., Grant I., Yu E., Levy P., Klauber M.R., Liu W.T.: The prevalence of dementia and Alzheimer’s disease (AD) in Shanghai, China: impact of age, gender, and education. Ann. Neurol. 27: 428–437, 1990.
Dartigues J-F., Gagnon M., Michel P.: Le programme de recherche Paquid sur l’épidémiologie de la démence: méthodes et résultats initiaux. Rev. Neurol. (Paris) 147: 225–230, 1991.
Friedland R.P.: Epidemiology, education, and the ecology of Alzheimer’s disease. Neurology 43: 246–249, 1993.
Ott A., Breteler M.M.B., van Harskamp F., Claus J.J., van der Cammen T.J., Grobbee D.E., Hofman A.: Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam study. BMJ 310: 970–973, 1995.
Bonaiuto S., Rocca W.A., Lippi A.: Impact of education and occupation on prevalence of Alzheimer’s disease (AD) and multi-infarct dementia (MID) in Appignano, Macerata Province, Italy. Neurology 40 (Suppl. 1): 346, 1990.
Hagnell O., Franck A., Grasbeck A., Ohman R., Otterbeck L., Rorsman B.: Senile dementia of the Alzheimer type in the Lundby Study. II. An attempt to identify possible risk factors. Eur. Arch. Psychiatry Clin. Neurosci. 241: 231–235, 1992.
Katzman R.: Education and the prevalence of dementia and Alzheimer’s disease. Neurology 43: 13–20, 1993.
Dartigues J-F., Gagnon M., Mazaux J.M., Barberger-Gateau P., Commenges D., Letenneur L., Orgogozo J.M.: Occupation during life and memory performance in nondemented French elderly community residents. Neurology 42: 1697–1701, 1992.
Brenner D.E., Kukull W.A., van Belle G., Bowen J.D., McCormick W.C., Teri L., Larson E.B.: Relationship between cigarette smoking and Alzheimer’s disease in a population-based case-control study. Neurology 43: 293–300, 1993.
Graves A.B., van Duijn C.M., Chandra V., Fratiglioni L., Hey-man A., Jorm A.F., Kokmen E., Kondo K., Mortimer J.A., Rocca W.A., Shalat S.L., Soininen H., Hofman A.: Alcohol and tobacco consumption as risk factors for Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20 (Suppl. 2): S48-S57, 1991.
Letenneur L., Dartigues J-F., Commenges D., Barberger-Gateau P., Tessier J.F., Orgogozo J.M.: Tobacco consumption and cognitive impairment in elderly people. A population-based study Ann. Epidemiol. 4: 449–454, 1994.
van Duijn C.M., Hofman A.: Relation between nicotine intake and Alzheimer’s disease BMJ 302: 1491–1494, 1991.
Prince M., Cullen M., Mann A.: Risk factors for Alzheimer’s disease and dementia: a case-control study based on the MRC elderly hypertension trial Neurology 44: 97–104, 1994.
Wang H., Fratiglioni L., Frisoni G.B., Viitanen M., Winblad B.: Smoking and the occurrence of Alzheimer’s disease: cross-sectional and longitudinal data in a population-based study Am. J. Epidemiol. 149: 640–644, 1999.
Tyas S., Koval J.J., Pederson L.L.: Does an interaction between smoking and drinking influence the risk of Alzheimer’s disease? Results from three Canadian studies Stat. Med. 19: 1685–1696, 2000.
Nourhashémi F., Gillette-Guyonnet S., Andrieu S., Ghisolfi A., Ousset P.J., Grandjean H., Grand A., Pouls J., Vellas B., Albarede J.L.: Alzheimer disease: protective factors Am. J. Clin. Nutr. 71: 643S–649S, 2000.
Honjo H., Tanaka K., Kashiwagi T.: Senile dementia —Alzheimer’s type and estrogen Horm. Metab. Res. 27: 204–207, 1995.
Yaffe K., Sawaya G., Lieberburg I., Grady D.: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia JAMA 279: 688–695, 1998.
Thomas T., Rhodin J.: Vascular actions of estrogen and Alzheimer disease Ann. N.Y. Acad. Sci. 903: 501–509, 2000.
Green P.S., Simpkins J.W.: Estrogens and estrogen-like non-feminizing compounds: their role in the prevention and treatment of Alzheimer’s disease Ann. N.Y. Acad. Sci. 924: 93–98, 2000.
Wang P.N., Liao S.Q., Liu R.S., Liu C.Y., Chao H.T., Lu S.R., Yu H.Y., Wang S.J., Liu H.C.: Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study Neurology 54: 2061–2066, 2000.
Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R., Koss E., Pfeiffer E., Jin S., Gamst A., Grundman M., Thomas R., Thal L.J.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer Disease: a randomized controlled trial JAMA 283: 1007–1015, 2000.
Henderson V.W., Paganini-Hill A., Miller B.L., Elble R.J., Reyes P.F., Shoupe D., McCleary C.A., Klein R.A., Hake A.M., Farlow M.R.: Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial Neurology 54: 295–301, 2000.
Marder K., Sano M.: Estrogen to treat Alzheimer’s disease: too little, too late? Neurology 54: 2035–2037, 2000.
McGeer P.L., Schulzer M., McGeer E.G.: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies Neurology 47: 425–432, 1996.
Pasinetti G.M.: Cyclooxygenase and inflammation in Alzheimer’s disease: experimental approaches and clinical interventions J. Neurosci. Res. 54: 1–6, 1998.
Breitner J.C.S., Gau B.A., Welsh K.A., Plassman B.L., McDonald W.M., Helms M.J., Anthony J.C.: Inverse association of anti-inflammatory treatments and Alzheimer’s disease: Initial results of a cotwin control study Neurology 44: 227–232, 1994.
Stewart W.F., Kawas C., Corrada M., Metter E.J.: Risk of Alzheimer’s disease and duration of NSAID use Neurology 48: 626–632, 1997.
McGeer P.L., McGeer E., Rogers J., Sibley J.: Anti-inflammatory drugs and Alzheimer disease Lancet 335: 1037, 1990.
Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P.: Clinical trial of indomethacin in Alzheimer’s disease Neurology 43: 1609–1611, 1993.
Bruce-Jones P.N., Crome P., Kalra L.: Indomethacin and cognitive function in healthy elderly volunteers Br. J. Clin. Pharmacol. 38: 45–51, 1994.
Rosenberg R.N., Richter R.W., Risser R.C., Taubman K., Prado-Farmer I., Ebalo E., Posey J., Kingfisher D., Dean D., Weiner M.F., Svetlik D., Adams P., Honig L.S., Cullum C.M., Schaefer F.V.: Genetic factors for the development of Alzheimer disease in the Cherokee Indian Arch. Neurol. 53: 997–1000, 1996.
Hendrie H.C., Hall K.S., Pillay N., Rodgers D., Prince C., Norton J., Brittain H., Nath A., Blue A., Kaufert J.: Alzheimer’s disease is rare in Cree Int. Psychogeriatr. 5: 5–14, 1993.
Paganini-Hill A., Henderson V.W.: Estrogen replacement therapy and risk of Alzheimer disease Arch. Intern. Med. 156: 2213–2217, 1996.
Broe G.A., Creasey H., Jorm A.F., Bennett H.P., Casey B., Waite L.M., Grayson D.A., Cullen J.: Health habits and risk of cognitive impairment and dementia in old age: a prospective study on the effects of exercise, smoking and alcohol consumption Aust. N.Z. J. Public Health 22: 621–623, 1998.
Jaendel C., Nicolas M.B., Dubois E., Nabet-Belleville F., Penin F., Cuny G.: Lipid peroxidation and free radical scavengers in Alzheimer’s disease Gerontology 35: 275–282, 1989.
Carr D.B., Goate A., Phil D., Morris J.C.: Current concepts in the pathogenesis of Alzheimer’s disease Am. J. Med. 103: 1S–2S, 1997.
Beilby J., Rossi E.: Broadsheet number 58: homocysteine and disease Pathology 32: 262–273, 2000.
Diaz-Arrastia R.: Hyperhomocysteinemia: a new risk factor for Alzheimer disease? Arch. Neurol. 55: 1407–1408, 1998.
Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., Ueland P.M.: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease Arch. Neurol. 55: 1449–1455, 1998.
Orgogozo J., Dartigues J-F., Lafont S., Letenneur L., Com-menges D., Salamon R.: Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area Rev. Neurol. (Paris) 153: 185–192, 1997.
Launer L.J., Feskens E.J.M., Kalmijn S., Kromhout D.: Smoking, drinking, and thinking. The Zutphen Elderly Study Am. J. Epidemiol. 143: 219–227, 1996.
Ruitenberg A., Swieten J.C., Hofman A., Breteler M.M.B.: Alcohol consumption and risk of dementia: results from the Rotterdam Study Neurobiol Aging 21 (Suppl. 1): S247, 2000.
Tredici G., Miloso M., Nicolini G., Galbiati S., Cavaletti G., Bertelli A.: Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Drugs Exp. Clin. Res. 25: 99–103, 1999.
Crawford J.G.: Alzheimer’s disease risk factors as related to
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McDowell, I. Alzheimer’s disease: Insights from epidemiology. Aging Clin Exp Res 13, 143–162 (2001). https://doi.org/10.1007/BF03351474
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03351474